CXCL1 and neoplasm: CXCR2 and its ligand CXCL1 contribute to the resistance of chemotherapy in mammary tumor cells and the knockdown of CXCR2 enhances sensitivity to chemotherapy and inhibits tumor cell metastasis [50, 51].